What is the reason for the revised Medical segment profit guidance?

The Medical segment profit guidance was revised downwards primarily due to approximately $25 million in inventory charges. These charges are related to the company's gloves portfolio, including those used in non-healthcare industries, as part of ongoing simplification efforts.

Has Cardinal Health changed its full-year earnings per share (EPS) guidance?

No, Cardinal Health reaffirmed its previously announced guidance range for fiscal year 2023 non-GAAP diluted earnings per share, which remains between $5.05 and $5.40.

What are the potential risks mentioned in the filing that could affect future performance?

The filing highlights several risks including ongoing inflationary pressures, supply chain constraints, competitive pressures in its business lines, risks associated with generic pharmaceutical pricing, and potential challenges in managing self-insurance losses or sourcing/manufacturing certain products. These factors could materially impact actual results.

Where can investors find more information or listen to the presentation mentioned?

The company stated that information on its use of non-GAAP financial measures is available in its SEC filings. A live webcast of the presentation at the Morgan Stanley Global Healthcare Conference was available on Cardinal Health's Investor Relations page at ir.cardinalhealth.com.

CAH 8-K: Regulation FD — Sep 13, 2022

Summary

Cardinal Health Inc. (CAH) issued a Form 8-K on September 13, 2022, to update its financial guidance for the Medical segment's profit in the first quarter of fiscal year 2023. The company now expects a Medical segment loss ranging from $55 million to $25 million, a downward revision from its prior guidance of a $20 million loss to a $20 million profit. This adjustment is primarily driven by approximately $25 million in inventory charges related to the company's gloves portfolio, including charges for the sale of certain disposable gloves utilized in non-healthcare industries, stemming from ongoing simplification efforts. Despite the revised Medical segment outlook, Cardinal Health reaffirmed its full fiscal year 2023 non-GAAP diluted earnings per share guidance of $5.05 to $5.40. The company also noted that it will present this update at the Morgan Stanley 20th Annual Global Healthcare Conference on the same day, September 13, 2022. Investors should note the company's caution regarding forward-looking statements and the potential impact of various risks, including inflationary pressures, supply chain constraints, and competitive dynamics, on future results.

Key Highlights

1Medical segment loss now expected to be between $55 million and $25 million for Q1 FY2023, a downward revision from previous guidance.
2The change is primarily due to approximately $25 million in inventory charges related to the Medical segment's gloves portfolio.
3These inventory charges include impacts from the sale of disposable gloves used in non-healthcare industries as part of simplification efforts.
4Fiscal year 2023 non-GAAP diluted earnings per share guidance of $5.05 to $5.40 was reaffirmed.
5The company presented this update at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022.
6Cardinal Health continues to face risks including inflationary pressures, supply chain constraints, and competitive pressures that could impact future results.
7The company does not provide forward-looking guidance on a GAAP basis due to the unpredictability of certain financial information.

CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Sep 13, 2022)

Summary

Key Highlights

Frequently Asked Questions